Evidence map›Paper›PMID 18803000›Full record

Trial reportThe American journal of gastroenterology2008

Effects of amitriptyline on gastric sensorimotor function and postprandial symptoms in healthy individuals: a randomized, double-blind, placebo-controlled trial.

Ernest P Bouras, Nicholas J Talley, Michael Camilleri, Duane D Burton, Michael G Heckman, Julia E Crook, Elliott Richelson

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in The American journal of gastroenterology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Observational
  9. Esophageal bezoar due to karaya gum granules used as a laxative.Clinical journal of gastroenterology · 2017
    Article
  10. Current and Emerging Medical Therapies for Gastroparesis.Current treatment options in gastroenterology · 2015
    Article
  11. Treatment of functional dyspepsia and gastroparesis.Current treatment options in gastroenterology · 2014
    Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Functional dyspepsia.Therapeutic advances in gastroenterology · 2010
    Article
  19. Antidepressants in functional dyspepsia.Expert review of gastroenterology & hepatology · 2010
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Ernest P BourasDivision of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida 32211, USA.
Nicholas J Talley
Michael Camilleri
Duane D Burton
Michael G Heckman
Julia E Crook
Elliott Richelson
Jacksonville College · USMayo Clinic in Florida · USMayo Clinic · US

Funding

ALPHA 2 ADRENERGIC CONTROL OF COLONIC FUNCTION IN IBSR01DK054681 · NIDDK · MAYO CLINIC ROCHESTER · PI CAMILLERI, MICHAEL L · 1999 to 2007
$1.5M
ALPHA 2 ADRENERGIC CONTROL IN IRRITABLE BOWEL SYNDROMEK24DK002638 · NIDDK · MAYO CLINIC ROCHESTER · PI CAMILLERI, MICHAEL L. · 1999 to 2008
$1.1M
NIDDK NIH HHS K24 DK002638NIDDK NIH HHS K24 DK 02638NIDDK NIH HHS R01 DK054681NIDDK NIH HHS R01 DK 54681PHS HHS U01 065713-01
6 · The paper itself

Abstract

backgroundLow-dose tricyclic antidepressants have been used to treat chronic somatic and gastrointestinal pain disorders, including refractory functional dyspepsia. However, there are only limited data on the effects of these drugs on upper gastrointestinal function.

aimTo compare the effects of two doses of amitriptyline (AMT) and placebo on gastric accommodation, emptying, satiation, and postprandial symptoms in healthy volunteers.

methodsUsing a parallel-group, double-blind, placebo-controlled design, 41 healthy volunteers were randomized to AMT 25 mg, AMT 50 mg, or placebo for 2 wk. During the final 3 days of therapy, the following end points were assessed: fasting and postprandial gastric volumes, 2- and 4-h gastric emptying, time and volume to maximum satiation using a nutrient drink test, and postprandial symptoms 30 min later using 10-cm visual analog scales. AMT and metabolite levels were measured.

resultsAMT slowed gastric emptying at 2 h (median 75% for placebo, 57% for AMT 25 mg, 67% for AMT 50 mg; P= 0.037) and 4 h (median 98% for placebo, 96% for AMT 25 mg, 92% for AMT 50 mg; P= 0.003). AMT did not affect gastric volumes or satiation volume, but it did reduce nausea scores at 30 min in a dose-dependent manner (median 2.1 for placebo, 0.9 for AMT 25 mg, and 0.0 for AMT 50 mg; P= 0.009).

conclusionIn healthy volunteers, AMT slows gastric emptying of solids, but it does not significantly affect gastric volumes or satiation. AMT reduces nausea after challenge with a high calorie liquid load.

Indexed as

AdultAmitriptylineAntidepressive Agents, TricyclicDose-Response Relationship, DrugDouble-Blind MethodFemaleGastric EmptyingHumansMaleMiddle AgedOrgan SizePostprandial PeriodRadionuclide ImagingSatiationStomachAmitriptylineAntidepressive Agents, Tricyclic

Identifiers

PMID18803000
PMCPMC3897125
OpenAlexW2015630427

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.